Day: November 17, 2022

Trip.com analysis: As off-season demand continues to grow Is there such a thing as an off-season in the post pandemic world

SINGAPORE, Nov. 17, 2022 /PRNewswire/ — Analysis of recent Trip.com data leads us to question whether on and off-season travel is becoming a thing of the past following the pandemic.  Increased demand for overseas travel, coupled with more flexible work schedules in remote working environments, appears to be producing a trend towards year-round demand to many […]

Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

–While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval in China will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the approval of the […]

RemeGen’s Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines

YANTAI, China, Nov. 17, 2022 /PRNewswire/ — RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced on November 5 that the Company’s self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been officially included in the newly released Chinese Society of Clinical Oncology (CSCO) 2022 Guidelines for the Treatment […]

Back To Top